Diethylpropion and mazindol: An end to the discussion?

被引：3

作者：

Lucchetta, Rosa Camila ^{[1
]}

Riveros, Bruno Salgado ^{[1
]}

Pontarolo, Roberto ^{[1
]}

Radominski, Rosana Bento ^{[2
]}

Otuki, Michel Fleith ^{[3
]}

Fernandez-Llimos, Fernando ^{[4
]}

Correr, Cassyano Januario ^{[1
]}

机构：

[1] Univ Fed Parana UFPR, Pharm Dept, Lab Clin Serv & Evidence Hlth, Curitiba, PR, Brazil

[2] UFPR, Hosp Clin, Serv Endocrinol & Metab, Curitiba, PR, Brazil

[3] Univ Estadual Ponta Grossa UEPG, Dept Pharmaceut Sci, Ponta Grossa, PR, Brazil

[4] Univ Lisbon, Fac Pharm, Dept Social Pharm, Res Inst Med iMed ULisboa, Lisbon, Portugal

来源：

REVISTA DA ASSOCIACAO MEDICA BRASILEIRA | 2017年 / 63卷 / 03期

关键词：

obesity; weight loss; treatment outcome; evidence-based practice; ANTIOBESITY DRUGS; WEIGHT-LOSS; EFFICACY; OBESITY; TRIALS; SAFETY;

D O I：

10.1590/1806-9282.63.03.203

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Antiobesity pharmacotherapy remains the main point of disagreement among both scientists and regulators. This is probably due to small sample sizes, high levels of heterogeneity, and low methodological quality. For many years, Brazil was one of the largest consumers of appetite suppressants worldwide, with evidence of irrational use of this drug class. Therefore, the country was the scene of a debate that divided the Brazilian Health Surveillance Agency (Anvisa-Agencia Nacional de Vigilancia Sanitaria) and medical societies over the maintenance record of diethylpropion, mazindol and fenproporex. In this context, this commentary presents new arguments to contribute to the discussion, as well as recommendations for future studies.

引用

页码：203 / 206

页数：4

共 21 条

[1] Abeso, 2011, COM OF
[2] Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events?
Als-Nielsen, B
Chen, WD
Gluud, C
Kjaergard, LL
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07): : 921 - 928
[3] [Anonymous], 2014, Global Health Observatory
[4] Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, Caroline M
Aronne, Louis J.
Bessesen, Daniel H.
McDonnell, Marie E.
Murad, M. Hassan
Pagotto, Uberto
Ryan, Donna H.
Still, Christopher D.
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (02) : 342 - 362
[5] The efficacy and safety of sibutramine for weight loss - A systematic review
Arterburn, DE
Crane, PK
Veenstra, DL
[J]. ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (09) : 994 - 1003
[6] Update on obesity pharmacotherapy
Bray, George A.
Ryan, Donna H.
[J]. YEAR IN DIABETES AND OBESITY, 2014, 1311 : 1 - 13
[7] Evidence-Based Public Health: A Fundamental Concept for Public Health Practice
Brownson, Ross C.
Fielding, Jonathan E.
Maylahn, Christopher A.
[J]. ANNUAL REVIEW OF PUBLIC HEALTH, 2009, 30 : 175 - 201
[8] The effect of antiobesity drugs on waist circumference: a mixed treatment comparison
Chilton, M.
Dunkley, A.
Carter, P.
Davies, M. J.
Khunti, K.
Gray, L. J.
[J]. DIABETES OBESITY & METABOLISM, 2014, 16 (03) : 237 - 247
[9] Martins MDDE, 2011, REV ASSOC MED BRAS, V57, P570, DOI 10.1590/S0104-42302011000500017
[10] Evidence Synthesis for Decision Making 2: A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials
Dias, Sofia
Sutton, Alex J.
Ades, A. E.
Welton, Nicky J.
[J]. MEDICAL DECISION MAKING, 2013, 33 (05) : 607 - 617

← 1 2 3 →